News about "Chugai Pharmaceutical "

Chugai Licenses RAF-MEK Molecular Glue SPYK04 to InxMed

Chugai Pharmaceutical grants InxMed an exclusive worldwide licence for SPYK04, a RAF-MEK molecular glue being developed for solid tumours.

Chugai Pharmaceutical | 30/09/2026 | By News Bureau |  113

Chugai Files for Expanded Tecentriq Use in MSI-High Colon Cancer in Japan

Chugai Pharmaceutical has filed a Japanese regulatory application seeking an expanded Tecentriq indication for adjuvant treatment of MSI-High colon cancer. The filing is backed by Phase 3 ATOMIC data showing three-year disease-free survival of 86.3 percent with Tecentriq plus mFOLFOX6, versus 76.2 percent with chemotherapy alone.

Chugai Pharmaceutical | 17/08/2026 | By News Bureau |  147

Chugai Pharma's Avastin Secures Approval in Japan for Additional Indication

Chugai Pharma’s Avastin has received approval in Japan for an additional indication, becoming the world’s first therapeutic option for neurofibromatosis type 2. The approval is supported by positive phase 2 clinical study results.

Chugai Pharmaceutical | 22/06/2026 | By News Bureau |  182

Chugai Files Regulatory Application in Japan for IgA Nephropathy Drug Sparsentan

Chugai Pharmaceutical has applied for regulatory approval in Japan for sparsentan, a dual-action oral therapy for IgA nephropathy. Clinical studies showed significant reductions in proteinuria and potential benefits in preserving kidney function, offering hope for patients with limited treatment options.

Chugai Pharmaceutical | 20/06/2026 | By News Bureau |  294

Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan

Chugai Pharmaceutical has received regulatory approval in Japan for the expanded use of Alecensa (alectinib) in advanced or recurrent ALK fusion-positive solid tumours, marking the world’s first tumour-agnostic approval for an ALK inhibitor.

Chugai Pharmaceutical | 19/05/2026 | By News Bureau |  283

Chugai Pharmaceutical Files Japan Approval for Gazyva in Idiopathic Nephrotic Syndrome

Chugai Pharmaceutical files a regulatory application in Japan for Gazyva to treat Idiopathic Nephrotic Syndrome (INS), based on phase 3 INShore study results.

Chugai Pharmaceutical | 15/05/2026 | By News Bureau |  129

Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD

Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.

Chugai Pharmaceutical | 25/03/2026 | By News Bureau |  435

Chugai Pharmaceutical Secures Global First Approval for Lunsumio' Polivy Combo in Relapsed Large B-Cell Lymphoma

Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.

Chugai Pharmaceutical | 24/03/2026 | By News Bureau |  200

Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan

Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.

Chugai Pharmaceutical | 23/02/2026 | By News Bureau |  391

Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia

Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.

Chugai Pharmaceutical | 24/10/2025 | By Dineshwori |  691